—Clinicians may be underestimating the cognitive burden on patients with MS, underscoring the need for more comprehensive cognitive assessments and assessing patient-reported outcomes. A growing body ...

Most patients with early active relapsing-remitting MS treated with ocrelizumab did not see worse hand function or ambulation ...

Researchers recently compared outcomes between patients who followed a 6-month weight-loss intervention program and those who received treatment as usual. Participants in the intervention group ...

Medthera's WalkPort is designed to help people with mobility and gait issues, including those with MS, safely stand and ...

(ABC 6 News)–A major grant has been awarded to MercyOne, to purchase specialized therapy equipment for people battling MS.

Andrew N. Wilner, MD: This is Dr Andrew Wilner, reporting for Medscape. Today I have the pleasure of interviewing Dr John Carter, Associate Professor at the Mayo Clinic, and a specialist in multiple ...

Neuraly, Inc., a wholly owned subsidiary of D&D Pharmatech, Inc. (KOSDAQ: 347850), announced that the first patient has been dosed in a Phase 2 Investigator-Initiated Trial (IIT) evaluating ...

Multiple sclerosis (MS) is a chronic autoimmune disease in which the immune system attacks the body’s nerves. Immune cells will breakdown the myelin sheath around the nerve fibers that help transport ...

MS patients in the U.S. with commercial insurance wait more than 50 days on average for a first visit to a neurologist, a ...

A study finds MS cases in England have doubled since 2000, with health inequalities leading to higher mortality in poorer areas despite advances in treatment.